JP7127019B2 - 細胞性ｖａｍｐ切断アッセイ - Google Patents

細胞性ｖａｍｐ切断アッセイ Download PDF

Info

Publication number
JP7127019B2
JP7127019B2 JP2019519721A JP2019519721A JP7127019B2 JP 7127019 B2 JP7127019 B2 JP 7127019B2 JP 2019519721 A JP2019519721 A JP 2019519721A JP 2019519721 A JP2019519721 A JP 2019519721A JP 7127019 B2 JP7127019 B2 JP 7127019B2
Authority
JP
Japan
Prior art keywords
vamp
bont
seq
epitope
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019519721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537567A (ja
Inventor
グレイ，ブリオニー
キャッド，ヴェリティ
ベアード，マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of JP2019537567A publication Critical patent/JP2019537567A/ja
Priority to JP2022087418A priority Critical patent/JP7656571B2/ja
Application granted granted Critical
Publication of JP7127019B2 publication Critical patent/JP7127019B2/ja
Priority to JP2024103017A priority patent/JP2024123229A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2019519721A 2016-10-18 2017-10-18 細胞性ｖａｍｐ切断アッセイ Active JP7127019B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022087418A JP7656571B2 (ja) 2016-10-18 2022-05-30 細胞性ｖａｍｐ切断アッセイ
JP2024103017A JP2024123229A (ja) 2016-10-18 2024-06-26 細胞性ｖａｍｐ切断アッセイ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16194390.7A EP3312290A1 (en) 2016-10-18 2016-10-18 Cellular vamp cleavage assay
EP16194390.7 2016-10-18
PCT/EP2017/076569 WO2018073288A1 (en) 2016-10-18 2017-10-18 Cellular vamp cleavage assay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022087418A Division JP7656571B2 (ja) 2016-10-18 2022-05-30 細胞性ｖａｍｐ切断アッセイ

Publications (2)

Publication Number Publication Date
JP2019537567A JP2019537567A (ja) 2019-12-26
JP7127019B2 true JP7127019B2 (ja) 2022-08-29

Family

ID=57208094

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019519721A Active JP7127019B2 (ja) 2016-10-18 2017-10-18 細胞性ｖａｍｐ切断アッセイ
JP2022087418A Active JP7656571B2 (ja) 2016-10-18 2022-05-30 細胞性ｖａｍｐ切断アッセイ
JP2024103017A Pending JP2024123229A (ja) 2016-10-18 2024-06-26 細胞性ｖａｍｐ切断アッセイ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022087418A Active JP7656571B2 (ja) 2016-10-18 2022-05-30 細胞性ｖａｍｐ切断アッセイ
JP2024103017A Pending JP2024123229A (ja) 2016-10-18 2024-06-26 細胞性ｖａｍｐ切断アッセイ

Country Status (5)

Country Link
US (2) US11193931B2 (enExample)
EP (2) EP3312290A1 (enExample)
JP (3) JP7127019B2 (enExample)
CN (2) CN119529053A (enExample)
WO (1) WO2018073288A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011348204B2 (en) 2010-12-22 2017-03-02 President And Fellows Of Harvard College Continuous directed evolution
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
EP3365356B1 (en) 2015-10-23 2023-06-28 President and Fellows of Harvard College Nucleobase editors and uses thereof
EP4212545A1 (en) * 2016-07-08 2023-07-19 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
WO2018081282A1 (en) * 2016-10-25 2018-05-03 Cellsnap Llc Neurotoxins and uses thereof
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College Evolution of trna synthetases
EP3673059A4 (en) 2017-08-25 2021-09-01 President And Fellows Of Harvard College EVOLUTION OF BONT PEPTIDASES
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
KR102017240B1 (ko) * 2018-08-23 2019-09-02 주식회사 하울바이오 Snare 복합체를 억제하는 항-vamp2 항체 및 이의 용도
WO2021011579A1 (en) * 2019-07-15 2021-01-21 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528724A (ja) 2011-09-29 2014-10-30 セルスナップ、リミテッド・ライアビリティ・カンパニー 毒素産生性試験のための組成物および方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
GB9411138D0 (en) * 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
FR2809733B1 (fr) 2000-06-02 2004-04-30 Inst Nat Sante Rech Med Substrat peptidique reconnu par la toxine botulique de type bont/b et son utilisation pour doser et/ou detecter ladite toxine ou des inhibiteurs correspondants
AU2002228887B2 (en) * 2000-11-06 2006-08-24 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
GB0115581D0 (en) * 2001-06-26 2001-08-15 Glaxo Group Ltd Method of mass spectometry
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7611856B2 (en) * 2003-11-05 2009-11-03 Los Alamos National Security, Llc Mass spectrometry-based methods for detection and differentiation of botulinum neurotoxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006026780A1 (en) 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
GB0425795D0 (en) 2004-11-24 2004-12-22 Givaudan Sa Composition
CA2588292C (en) 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8052979B2 (en) 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DE602006013481D1 (de) 2005-09-19 2010-05-20 Allergan Inc Mit clostriedientoxin aktivierbare clostridientoxine
EP2001902B1 (en) 2006-03-14 2013-03-27 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US8753831B2 (en) * 2007-06-05 2014-06-17 City Of Hope Methods for detection of botulinum neurotoxin
CN101932936B (zh) * 2007-09-14 2016-04-27 拜奥麦迪逊公司 利用切割序列和间隔子的共振能量转移测定
US8940477B2 (en) * 2007-11-08 2015-01-27 Wisconsin Alumni Research Foundation Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action
CA2727082C (en) 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
CN102083451A (zh) 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
GB0815264D0 (en) 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303788A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303783A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20110070211A1 (en) 2009-08-14 2011-03-24 Allergan, Inc. Methods of Treating Cancer Using Galanin Retargeted Endopepidases
AU2010282273A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
CN102573877A (zh) 2009-08-14 2012-07-11 阿勒根公司 使用神经营养蛋白再靶向内肽酶治疗癌症的方法
EP2464659A1 (en) 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
WO2011020119A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2013011055A1 (en) * 2011-07-19 2013-01-24 ETH Zürich Means and methods for determining clostridial neurotoxins
US20140287433A1 (en) * 2011-07-19 2014-09-25 ETH Zürich Means and methods for determining clostridial neurotoxins
CN108178801B (zh) 2012-05-30 2022-05-03 哈佛大学校长及研究员协会 工程化的肉毒神经毒素
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
HK1210190A1 (en) * 2012-11-21 2016-04-15 Merz Pharma Gmbh & Co. Kgaa. Means and methods for determination of botulinum neurotoxin biological activity
GB201303108D0 (en) 2013-02-21 2013-04-10 Syntaxin Ltd Therapeutics for suppressing osteoporosis
MX360513B (es) * 2013-06-28 2018-11-07 Merz Pharma Gmbh & Co Kgaa Medios y metodos para la determinacion de la actividad biologica de polipeptidos de neurotoxina en celulas.
GB201312295D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Suppression of itch
EP3312290A1 (en) * 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528724A (ja) 2011-09-29 2014-10-30 セルスナップ、リミテッド・ライアビリティ・カンパニー 毒素産生性試験のための組成物および方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Applied and Environmental Microbiology，1999年，Vol. 65, No. 9，pp. 3787-3792
Biologicals，2010年，Vol. 38, No. 1，pp. 113-119
Journal of Clinical Microbiology，1996年，Vol. 34, No. 8，pp. 1934-1938
The Journal of Biological Chemistry，2008年，Vol. 283, No. 30，pp. 21153-21159

Also Published As

Publication number Publication date
WO2018073288A1 (en) 2018-04-26
RU2019113794A (ru) 2020-11-20
JP7656571B2 (ja) 2025-04-03
JP2019537567A (ja) 2019-12-26
EP3529370A1 (en) 2019-08-28
JP2022130378A (ja) 2022-09-06
US12493035B2 (en) 2025-12-09
US20220113310A1 (en) 2022-04-14
RU2019113794A3 (enExample) 2021-09-10
JP2024123229A (ja) 2024-09-10
EP3312290A1 (en) 2018-04-25
US20190219575A1 (en) 2019-07-18
CN109844130A (zh) 2019-06-04
CN119529053A (zh) 2025-02-28
CN109844130B (zh) 2024-10-11
US11193931B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
JP7656571B2 (ja) 細胞性ｖａｍｐ切断アッセイ
US11332518B2 (en) Immuno-based botulinum toxin serotype A activity assays
US20210172952A1 (en) Immuno-based retargeted endopeptidase activity assays
TWI632369B (zh) 用於測定細胞中神經毒素多肽之生物活性的工具及方法
US8618261B2 (en) Immuno-based botulinum toxin serotype A activity assays
JP6772138B2 (ja) 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法
RU2807994C2 (ru) Анализ расщепления клеточного vamp
HK40008973B (zh) 细胞vamp切割测定
HK40008973A (en) Cellular vamp cleavage assay
HK40016334A (en) Immuno-based botulinum toxin serotype a activity assays
HK1169855B (en) Immuno-based retargeted endopeptidase activity assays
AU2017210625A1 (en) Immuno-based botulinum toxin serotype A activity assays
HK1151298B (en) Immuno-based botulinum toxin serotype a activity assays

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220530

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220530

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220608

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20220630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220706

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220810

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220817

R150 Certificate of patent or registration of utility model

Ref document number: 7127019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250